CAJ | 학술논문

肺癌是目前全世界发病率第一、死亡率最高的肿瘤。肺癌的早期诊断和有效治疗是提高患者生存率的关键。miR-NA是一类内源性、高度保守的非编码小分子RNA，在肺癌的发生、发展中起着重要作用。近年来，肺癌诊断、治疗和预后判断分子标志物miRNA的研究进展迅速，本文就miRNA作为肺癌早期诊断、预后判断和疗效预测分子标志物的研究进展，以及目前存在的问题做一综述。
폐암시목전전세계발병솔제일、사망솔최고적종류。폐암적조기진단화유효치료시제고환자생존솔적관건。miR-NA시일류내원성、고도보수적비편마소분자RNA，재폐암적발생、발전중기착중요작용。근년래，폐암진단、치료화예후판단분자표지물miRNA적연구진전신속，본문취miRNA작위폐암조기진단、예후판단화료효예측분자표지물적연구진전，이급목전존재적문제주일종술。
Lung cancer has the highest morbidity and mortality rate among malignant tumors. Early diagnosis and effective treat-ment are the keys to improving the survival of lung cancer patients. A type of endogenous, highly conserved, non-coding small mole-cule RNA (i.e., miRNA) was found to play an important role in the occurrence and development of this disease. Research on this molec-ular marker miRNA for the diagnosis, treatment and prognosis of lung cancer has rapidly progressed. This paper reviews the research work on miRNA as a molecular marker in the early diagnosis, treatment efficacy, and prognosis of lung cancer and explores some ques-tions related to this disease.